Guideline Management of Renal Failure

Introduction to Renal Failure Management

The American Journal of Kidney Diseases recommends considering eGFR when dosing all medications cleared by the kidneys 8
The Kidney International guideline suggests management of chronic kidney disease (CKD) should prioritize blood pressure control with RAAS inhibitors, SGLT2 inhibitors for cardio-renal protection, dietary sodium restriction to <2.3 g/day, protein intake of 0.8 g/kg/day for stages 3-5, and systematic medication dose adjustments based on eGFR 1

The European Heart Journal recommends initiating ACE inhibitors or ARBs in all CKD patients with hypertension or proteinuria, as these agents reduce microalbuminuria and slow progression to end-stage renal disease 2
The European Heart Journal suggests monitoring serum creatinine after initiating RAAS inhibitors, as an initial increase that returns to baseline is expected and acceptable; discontinue only if creatinine rises >30% and remains elevated 2

The Kidney International guideline recommends prescribing SGLT2 inhibitors for all adults with type 2 diabetes and CKD who have not achieved glycemic targets despite metformin, prioritizing agents with documented cardiovascular and kidney benefits 1
The Kidney International guideline suggests adding long-acting GLP-1 receptor agonists if glycemic targets remain unmet despite SGLT2 inhibitor use, choosing agents with proven cardiovascular benefits 1

The Kidney International guideline recommends restricting sodium to <2.3 g/day for all CKD patients to control blood pressure and reduce cardiovascular risk 1
The Diabetes Care journal suggests restricting phosphorus to 0.8-1.0 g/day when eGFR falls below 60 mL/min (typically stages 3-4) 5
The Kidney International guideline recommends maintaining protein at 0.8 g/kg body weight/day for CKD stages 3-5 to slow progression while preventing malnutrition 1

The European Heart Journal recommends reducing infusion to 1.0 mg/kg/h when creatinine clearance <30 mL/min for bivalirudin, and to 0.25 mg/kg/h for hemodialysis patients 2
The American Journal of Kidney Diseases suggests reviewing and limiting over-the-counter medicines and herbal remedies that may be harmful in CKD 8

The Kidney International guideline recommends implementing individualized approach for CKD G3-G5 with emergent hyperkalemia, including dietary and pharmacologic interventions 1
The Kidney International guideline suggests considering pharmacological treatment with or without dietary intervention to prevent acidosis when serum bicarbonate <18 mmol/L in adults 1

The Diabetes Care journal recommends monitoring eGFR, electrolytes, and therapeutic drug levels in CKD patients receiving medications with narrow therapeutic windows or nephrotoxic potential 5
The Kidney International guideline suggests monitoring nutritional status regularly through appetite assessment, dietary intake evaluation, body weight changes, and biochemical markers 1

The American Journal of Kidney Diseases recommends beginning patient education about treatment options when patients reach CKD stage 4 (eGFR <30 mL/min) 9